Cargando…
Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease()
Recent developments of PET amyloid ligands have made it possible to visualize the presence of Aβ deposition in the brain of living participants and to assess the consequences especially in individuals with no objective sign of cognitive deficits. The present review will focus on amyloid imaging in c...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3777672/ https://www.ncbi.nlm.nih.gov/pubmed/24179789 http://dx.doi.org/10.1016/j.nicl.2013.02.006 |
_version_ | 1782284999305723904 |
---|---|
author | Chételat, Gaël La Joie, Renaud Villain, Nicolas Perrotin, Audrey de La Sayette, Vincent Eustache, Francis Vandenberghe, Rik |
author_facet | Chételat, Gaël La Joie, Renaud Villain, Nicolas Perrotin, Audrey de La Sayette, Vincent Eustache, Francis Vandenberghe, Rik |
author_sort | Chételat, Gaël |
collection | PubMed |
description | Recent developments of PET amyloid ligands have made it possible to visualize the presence of Aβ deposition in the brain of living participants and to assess the consequences especially in individuals with no objective sign of cognitive deficits. The present review will focus on amyloid imaging in cognitively normal elderly, asymptomatic at-risk populations, and individuals with subjective cognitive decline. It will cover the prevalence of amyloid-positive cases amongst cognitively normal elderly, the influence of risk factors for AD, the relationships to cognition, atrophy and prognosis, longitudinal amyloid imaging and ethical aspects related to amyloid imaging in cognitively normal individuals. Almost ten years of research have led to a few consensual and relatively consistent findings: some cognitively normal elderly have Aβ deposition in their brain, the prevalence of amyloid-positive cases increases in at-risk populations, the prognosis for these individuals is worse than for those with no Aβ deposition, and significant increase in Aβ deposition over time is detectable in cognitively normal elderly. More inconsistent findings are still under debate; these include the relationship between Aβ deposition and cognition and brain volume, the sequence and cause-to-effect relations between the different AD biomarkers, and the individual outcome associated with an amyloid positive versus negative scan. Preclinical amyloid imaging also raises important ethical issues. While amyloid imaging is definitely useful to understand the role of Aβ in early stages, to define at-risk populations for research or for clinical trial, and to assess the effects of anti-amyloid treatments, we are not ready yet to translate research results into clinical practice and policy. More researches are needed to determine which information to disclose from an individual amyloid imaging scan, the way of disclosing such information and the impact on individuals and on society. |
format | Online Article Text |
id | pubmed-3777672 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-37776722013-10-31 Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease() Chételat, Gaël La Joie, Renaud Villain, Nicolas Perrotin, Audrey de La Sayette, Vincent Eustache, Francis Vandenberghe, Rik Neuroimage Clin Review Article Recent developments of PET amyloid ligands have made it possible to visualize the presence of Aβ deposition in the brain of living participants and to assess the consequences especially in individuals with no objective sign of cognitive deficits. The present review will focus on amyloid imaging in cognitively normal elderly, asymptomatic at-risk populations, and individuals with subjective cognitive decline. It will cover the prevalence of amyloid-positive cases amongst cognitively normal elderly, the influence of risk factors for AD, the relationships to cognition, atrophy and prognosis, longitudinal amyloid imaging and ethical aspects related to amyloid imaging in cognitively normal individuals. Almost ten years of research have led to a few consensual and relatively consistent findings: some cognitively normal elderly have Aβ deposition in their brain, the prevalence of amyloid-positive cases increases in at-risk populations, the prognosis for these individuals is worse than for those with no Aβ deposition, and significant increase in Aβ deposition over time is detectable in cognitively normal elderly. More inconsistent findings are still under debate; these include the relationship between Aβ deposition and cognition and brain volume, the sequence and cause-to-effect relations between the different AD biomarkers, and the individual outcome associated with an amyloid positive versus negative scan. Preclinical amyloid imaging also raises important ethical issues. While amyloid imaging is definitely useful to understand the role of Aβ in early stages, to define at-risk populations for research or for clinical trial, and to assess the effects of anti-amyloid treatments, we are not ready yet to translate research results into clinical practice and policy. More researches are needed to determine which information to disclose from an individual amyloid imaging scan, the way of disclosing such information and the impact on individuals and on society. Elsevier 2013-03-05 /pmc/articles/PMC3777672/ /pubmed/24179789 http://dx.doi.org/10.1016/j.nicl.2013.02.006 Text en © 2013 The Authors http://creativecommons.org/licenses/by-nc-sa/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Review Article Chételat, Gaël La Joie, Renaud Villain, Nicolas Perrotin, Audrey de La Sayette, Vincent Eustache, Francis Vandenberghe, Rik Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease() |
title | Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease() |
title_full | Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease() |
title_fullStr | Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease() |
title_full_unstemmed | Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease() |
title_short | Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease() |
title_sort | amyloid imaging in cognitively normal individuals, at-risk populations and preclinical alzheimer's disease() |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3777672/ https://www.ncbi.nlm.nih.gov/pubmed/24179789 http://dx.doi.org/10.1016/j.nicl.2013.02.006 |
work_keys_str_mv | AT chetelatgael amyloidimagingincognitivelynormalindividualsatriskpopulationsandpreclinicalalzheimersdisease AT lajoierenaud amyloidimagingincognitivelynormalindividualsatriskpopulationsandpreclinicalalzheimersdisease AT villainnicolas amyloidimagingincognitivelynormalindividualsatriskpopulationsandpreclinicalalzheimersdisease AT perrotinaudrey amyloidimagingincognitivelynormalindividualsatriskpopulationsandpreclinicalalzheimersdisease AT delasayettevincent amyloidimagingincognitivelynormalindividualsatriskpopulationsandpreclinicalalzheimersdisease AT eustachefrancis amyloidimagingincognitivelynormalindividualsatriskpopulationsandpreclinicalalzheimersdisease AT vandenbergherik amyloidimagingincognitivelynormalindividualsatriskpopulationsandpreclinicalalzheimersdisease |